Repurposing Safe Drugs to Modulate DNA Repair in CRISPR Editing

Study Background and Research Question

The repair of DNA double-strand breaks (DSBs) is a fundamental cellular process with major implications for genome editing, disease modeling, and cancer therapy. DSBs may occur spontaneously due to metabolic activity or be intentionally introduced at specific genomic loci using CRISPR-Cas9 nucleases. Cellular repair mechanisms for DSBs are diverse, including non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway leads to distinct genomic outcomes, ranging from small insertions/deletions (indels) to precise sequence integration or larger chromosomal changes. The capacity to influence which pathway predominates has the potential to refine genome editing outcomes and enable synthetic lethality approaches in targeted cancer treatment. This study asks: Can clinically approved small molecules be repurposed to modulate the choice of DSB repair pathway, thereby enhancing the precision and utility of CRISPR-based genome editing?

Key Innovation from the Reference Study

According to the reference study, the authors conducted a large-scale screening of over 7,000 FDA-approved drug conditions in human induced pluripotent stem cells (hiPSCs) expressing inducible Cas9. By systematically treating cells during CRISPR-induced DSBs, they quantified how distinct compounds shift the balance between NHEJ, MMEJ, and HDR. This approach not only identified drugs that promote or inhibit specific repair outcomes but also uncovered synergistic effects between genetic perturbations (such as ESR2 silencing) and pharmacological interventions. Importantly, the study provides a roadmap for using well-characterized, clinically safe molecules to direct genome editing outcomes or induce synthetic lethality in cancer cells with defined DNA repair defects.

Methods and Experimental Design Insights

The experimental workflow began with the generation of hiPSCs stably expressing a doxycycline-inducible Cas9 (iCRISPR system), enabling precise temporal control over DSB induction. The target gene (FRMD7) was selected for editing alongside administration of each drug condition. Following genome editing, cells were allowed to recover, and viability was measured with a resazurin fluorescence assay. DNA was then extracted and deep-sequenced to assess the nature and frequency of editing outcomes. The sequencing data were computationally assigned to specific repair pathways: indels without significant microhomology were attributed to NHEJ; deletions with ≥2 bp microhomology were classified as MMEJ; and precise edits using donor templates were counted as HDR events. The effect of each drug on cell survival and the distribution of repair outcomes was quantified relative to DMSO-treated controls. This high-throughput approach allowed parallel assessment of thousands of conditions in a robust, internally controlled manner.

Core Findings and Why They Matter

The study's systematic screening revealed several key insights:

• Pathway Modulation: Multiple clinically approved drugs were found to enhance or inhibit specific DSB repair mechanisms. For instance, known inhibitors of DNA-PKcs suppressed NHEJ, whereas PARP inhibitors modulated MMEJ, confirming the screen's validity.
• Synergy with Genetic Perturbations: Silencing ESR2 (estrogen receptor 2) significantly increased HDR when combined with NHEJ inhibition, achieving a mean 4.6-fold enhancement in precise genome editing.
• Synthetic Lethality: The screen identified drugs that are selectively toxic to cells deficient in NHEJ or HDR, highlighting candidates for targeted cancer therapy exploiting repair vulnerabilities.
• Potential for Precision Editing: By shifting pathway choice, it becomes possible to favor template-directed repair (HDR/SSTR) over error-prone end joining, reducing unwanted indels and improving the fidelity of gene correction strategies.

These findings are pivotal for researchers seeking to optimize genome editing protocols or develop therapies for genetic diseases where precise correction is needed. Furthermore, the identification of drug-pathway interactions supports the development of personalized cancer treatments based on tumor repair profiles.

Comparison with Existing Internal Articles

Several internal resources elaborate on related experimental strategies. For example, Dantrolene sodium salt is highlighted as a precision ryanodine receptor antagonist that enables advanced calcium signaling modulation in genome editing workflows. The use of dantrolene in these contexts aligns with the study's emphasis on pharmacologically tuning cellular pathways to influence DNA repair outcomes. Another resource, Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Workflows, describes how calmodulin-dependent RyR inhibition can fine-tune intracellular calcium flux—processes that intersect with DNA repair and cell survival. While the reference study primarily focuses on DNA repair pathways and drug repurposing, these internal articles provide practical workflow recommendations for implementing ryanodine receptor antagonists like dantrolene in complementary research, particularly where modulation of calcium homeostasis interfaces with genome stability and editing efficiency.

Limitations and Transferability

Despite its comprehensive scope, the screening was limited to hiPSCs and a single genomic target. Pathway preferences and drug effects may differ in primary cells, differentiated tissues, or across species. The reliance on cell viability as a readout for synthetic lethality also means that some context-specific or long-term effects may be overlooked. Additionally, while many drugs identified are clinically safe, their off-target effects or interactions with other cellular processes require further validation before translational application. The study does not directly address modulation of DNA repair in disease models such as neurodegeneration or ischemia, although these are logical next steps given the centrality of DSB repair and calcium signaling in such conditions.

Protocol Parameters

• Drug administration: Apply candidate drugs at concentrations validated for safety and efficacy in hiPSC cultures; typically, dosing mirrors clinically relevant plasma levels when feasible.
• CRISPR induction: Use doxycycline to activate Cas9 for precise temporal control of DSB induction; optimize timing to overlap with drug exposure.
• Editing outcome quantification: Employ deep sequencing of the target locus to resolve repair pathway outcomes (NHEJ, MMEJ, HDR) at single-nucleotide resolution.
• Cell viability assessment: Utilize resazurin or similar metabolic assays post-editing to identify conditions associated with synthetic lethality.
• Workflow extension: When exploring calcium signaling modulation in genome editing, consider ryanodine receptor antagonists (e.g., dantrolene sodium salt) to dissect links between calcium homeostasis and DNA repair pathway selection.

Research Support Resources

To experimentally modulate intracellular calcium signaling and investigate its impact on DNA repair dynamics, researchers can utilize Dantrolene, sodium salt (SKU B6329), a potent ryanodine receptor antagonist with nanomolar efficacy in RyR2 inhibition. APExBIO supplies this compound with high purity, supporting reproducible workflows in calcium signaling modulation, genome editing, and disease modeling. For further experimental guidance, the internal article Dantrolene Sodium Salt: Applied Ryanodine Receptor Antagonist Use-Cases details actionable protocol parameters and troubleshooting strategies relevant to this research domain.